Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 77Pancreatic Neoplasms 56Stomach Neoplasms 52Rectal Neoplasms 43Esophageal Squamous Cell Carcinoma 38Esophageal Neoplasms 38Neoplasm Metastasis 25Colonic Neoplasms 23Neoplasms 15Cholangiocarcinoma 13Liver Neoplasms 10Gastrointestinal Neoplasms 10Breast Neoplasms 9Adenocarcinoma Of Esophagus 9Carcinoma, Hepatocellular 7Anus Neoplasms 7Lung Neoplasms 6Head and Neck Neoplasms 6Biliary Tract Neoplasms 6Ovarian Neoplasms 5Melanoma 5Adenocarcinoma 5Kidney Neoplasms 4Gastrointestinal Diseases 4Digestive System Neoplasms 4Carcinoma, Squamous Cell 4Carcinoma, Non-Small-Cell Lung 4Uterine Cervical Neoplasms 3Sarcoma 3Lymphoma 3

Interventions

Radiosurgery 2Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unresectable Locally Recurrent Rectal Cancer × Drug Therapy × Gastrointestinal × Clear all
NCT06767007 2026-04-23

SBRT + PD-1 Antibody in Unresectable Locally Recurrent Rectal Cancer(SPARKLE)

Sixth Affiliated Hospital, Sun Yat-sen University

Phase 2 Recruiting
31 enrolled
Gastrointestinal

Unresectable Locally Recurrent Rectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡